Clinical Research Directory
Browse clinical research sites, groups, and studies.
Autologous Tenon's Capsule Autograft for Large and Recurrent Full-Thickness Macular Holes
Sponsor: Benha University
Summary
This prospective interventional clinical trial aims to evaluate the anatomical and functional outcomes of autologous Tenon's capsule autograft in the surgical management of large and recurrent full-thickness macular holes. Patients with large (\>400 µm), chronic, recurrent, or highly myopic macular holes will undergo 23-gauge pars plana vitrectomy with placement of an autologous Tenon's capsule graft into the macular hole followed by silicone oil tamponade. The primary outcome is anatomical macular hole closure confirmed by spectral-domain optical coherence tomography (SD-OCT). Secondary outcomes include best-corrected visual acuity, graft integration, and postoperative complications during a 6-month follow-up period.
Official title: Outcomes of Autologous Tenon's Capsule Autograft for Large and Recurrent Full-Thickness Macular Holes: A Prospective Interventional Clinical Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-07-05
Completion Date
2026-05-15
Last Updated
2026-08-12
Healthy Volunteers
No
Conditions
Interventions
Autologous Tenon's Capsule Autograft
Participants undergo standard 23-gauge pars plana vitrectomy for large or recurrent full-thickness macular holes. An autologous Tenon's capsule graft is harvested from the superior bulbar conjunctiva, trimmed to the appropriate size, and implanted into the macular hole under perfluorocarbon liquid. The procedure is completed with 5000-centistoke silicone oil tamponade. Patients are instructed to maintain face-down positioning for 5 to 7 days after surgery and are followed for 6 months to evaluate anatomical closure, visual outcomes, graft integration, and postoperative complications.
Locations (1)
Benha University
Banhā, Benha, Egypt